Mobile

A phase 3 trial studying how well lenvatinib works in treating patients with liver cancer who would not benefit from surgery compared against sorafenib. The trial is taking place worldwide, patients a...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-002992-33

A phase 3 trial studying how well lenvatinib works in treating patients with liver cancer who would not benefit from surgery compared against sorafenib. The trial is taking place worldwide, patients and their physician will know if they are receiving lenvatinib or sorafenib

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of the study is to compare overall survival (OS) in subjects treated with lenvatinib versus sorafenib as a first-line treatment in subjects with unresectable heptocellular carcinoma (HCC)

Critère d'inclusion

  • Unresectable Hepatocellular Carcinoma

Liens